Mike O’Donnell
Vice President Technical Operations, Alexion, AstraZeneca Rare Disease
It takes patients an average of 4.8 years and 7.3 specialist visits to receive a rare disease diagnosis. In rare disease medicine manufacturing, every second matters.
Advanced biologics and global distribution create a high‑stakes balancing act: pioneer scientific discovery, protect quality and get medicines to patients faster.
Scaling ultra‑rare therapies presents unique challenges: small batches, complex analytics and globally dispersed patients. “Our job is to overcome those challenges,” says Mike O’Donnell, Vice President, Technical Operations at Alexion, AstraZeneca Rare Disease. “Technical operations power everything from development to approvals to distribution. We’re designing with digital and AI tools that augment our already exceptional manufacturing practices.” O’Donnell explains how role‑based analytics ensure each team member gets the metrics and alerts that matter for their job. “So, we act faster, and only when it counts.” Harmonised GxP data governance moves teams from manual trending to exception‑based management and near‑real‑time decisions.
Build capability where the biology leads
“We follow the science and the technology — science sets the direction; tech speeds the journey. Our priority is an end‑to‑end digital thread that drives continuous and connected processing.” The result is faster cycle times and more right‑first‑time outcomes, with less waste and energy per batch because innovation must not increase environmental footprint. “We’re meeting our commitment to achieve carbon net zero by 2045 at pace,” says O’Donnell.
He cites Alexion’s transition later this year to biomethane to provide 100% of the heating needs at Dublin and Athlone manufacturing sites, HVO for road freight, 100% Sustainable Aviation Fuel for freight to Europe and reduced water usage YoY. “We’re proving you can move faster for patients and lighter for the planet.” Given the complexity and uncertainty of global supply chains, O’Donnell acknowledges the need for network resilience. “Predictive capacity modelling, digital supply chain twins — adaptability is built into our operations.”
We’re meeting our commitment to achieve carbon net zero by 2045 at pace
Self-healing supply chain and human collaboration
The company is also enhancing systems for a “self‑healing” supply chain — sensing disruptions early, correcting routine issues automatically and elevating complex decisions to expert teams quickly. The growing presence of parent company AstraZeneca is also increasing capacity at Alexion’s strategically critical Dublin campus, a legacy site. “We’re cross‑pollinating our rare disease manufacturing expertise with AstraZeneca’s technology and reach,” says O’Donnell. “A business‑friendly ecosystem that includes the IDA, HPRA and a supportive government sector also supports us in delivering treatments for patients.” That human collaboration can’t be underestimated, nor can talent. “Technology can augment operations, but our people are our core,” says O’Donnell. “When we get people with the right attitude and aptitude into a room together, we can solve problems and drive creativity.”
